Table 1.

Characteristics of the study population (n = 27 patients)

Characteristic	n	n (%)	Median (range)
Maternal
Demographic characteristics (n = 27)
Age (years) at the time of the third trimester pharmacokinetic evaluation	27		28.8 (15.2–39.1)
Race/ethnicity	27
White, non-Hispanic		2 (7.4)
Black, non-Hispanic		14 (51.9)
Hispanic		11 (40.7)
Second Trimester (n = 4)
Weight (kg)	4		71.9 (61.4–86.5)
Gestational age (weeks)	4		23.9 (23.3–26.7)
Duration (weeks) of receipt of nelfinavir before pharmacokinetic evaluation	4		6.4 (2.3–130.4)
CD4 lymphocyte count (cells/mL)	3		565 (411–1045)
Plasma HIV-1 RNA concentration (copies/mL)	3		4370 (400–55 859)
Plasma HIV-1 RNA concentration o400 copies/mL	3
Yes		0 (0)
No		3 (100)
Third trimester (n = 27)
Weight (kg)	27		77.5 (56.0–176.1)
Gestational age (weeks)	27		33.9 (30.9–38.3)
Duration (weeks) of receipt of nelfinavir before pharmacokinetic evaluation	27		16.6 (2.9–138.4)
CD4 lymphocyte count (cells/mL)	26		509 (194–1208)
Plasma HIV-1 RNA concentration (copies/mL)	26		75 (10–787)
Plasma HIV-1 RNA concentration o400 copies/mL	26
Yes		23 (88.5)
No		3 (11.5)
Delivery
Weight (kg)	22		84.1 (57.6–176.0)
CD4 lymphocyte count (cells/mL)	26		497 (172–1530)
Plasma HIV-1 RNA concentration (copies/mL)	27		75 (10–9953)
Plasma HIV-1 RNA concentration o400 copies/mL	27
Yes		22 (81.5)
No		5 (18.5)
Postpartum (n = 22)
Weight (kg)	21		73.2 (46.0–174.0)
Weeks after delivery	22		8.2 (6.1–12.4)
CD4 lymphocyte count (cells/mL)	16		555 (172–1530)
Plasma HIV-1 RNA concentration (copies/mL)	15		75 (25–1650)
Plasma HIV-1 RNA concentration o400 copies/mL	15
Yes		12 (80.0)
No		3 (20.0)
Infant (n = 27)
Birth weight (g)	27		2920 (2145–3630)
Length at birth (cm)	27		49.5 (43.5–53.3)
Gestational age (weeks)	27		38 (36–40)